TherapeuticsMD, Inc. (TXMD) Income Statement
TXMD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTXMD revenue and net income
Where TXMD's revenue goes
2025Each bar shows an amount and its share of revenue. TXMD kept −18.8% of revenue as net income.
TXMD profit margins
TXMD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +71.6% | −64.9% | −45.8% | −17.3% |
| Gross profit | +71.6% | −64.7% | −42.7% | −15.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | −81.9% | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TXMD quarterly EPS vs estimates
TherapeuticsMD beat the analyst EPS estimate in 4 of the last 6 quarters. Next report: November 11, 2026.
TXMD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M | $64.9M | $49.6M | $16.1M | $16.8M | $19.4M |
| Cost of revenue | $1.2M | $509,000 | $922,000 | $1.4M | $1.4M | $16.0M | $6.3M | $2.7M | $2.6M | $4.2M |
| Gross profit | $3.0M | $1.8M | $1.3M | $68.6M | $1.2M | $48.9M | $43.3M | $13.4M | $14.1M | $15.2M |
| Research & development | — | — | — | $5.5M | $7.1M | $10.4M | $19.8M | $27.3M | $33.9M | $53.9M |
| Sales, general & admin | $6.9M | $6.1M | $19.0M | $57.9M | $80.7M | $194.0M | $174.7M | $116.0M | $57.7M | $51.3M |
| Total operating expenses | $7.2M | $6.6M | $9.8M | $57.9M | $80.7M | $204.4M | $194.5M | $143.6M | $91.8M | $105.4M |
| Operating income | −$4.2M | −$4.8M | −$8.5M | $10.7M | −$79.6M | −$155.5M | −$151.2M | −$130.2M | −$77.6M | −$90.3M |
| Interest income | $142,000 | $135,000 | — | — | — | — | $0 | $0 | $7,699 | $10,824 |
| Interest expense | $8,000 | $9,500 | $200,000 | $12.3M | $32.9M | $28.6M | $17.4M | $4.7M | $0 | $0 |
| Income before taxes | −$653,000 | −$2.3M | −$7.7M | $1.1M | −$79.3M | −$183.5M | −$176.1M | −$132.6M | −$76.9M | −$89.9M |
| Income taxes | −$84,000 | −$31,000 | −$43,000 | −$91.9M | $33.2M | $29.2M | $19.9M | $2.3M | −$7,699 | $367,317 |
| Net income | −$569,000 | −$2.2M | −$10.3M | $112.0M | −$172.4M | −$183.5M | −$176.1M | −$132.6M | −$76.9M | −$89.9M |
| EBITDA | −$3.0M | −$4.3M | −$7.6M | $11.9M | −$78.8M | −$153.4M | −$158.2M | −$127.6M | −$76.7M | −$89.7M |
| EPS (diluted) | $0.07 | −$0.20 | −$0.88 | $11.80 | −$21.50 | −$33.50 | −$33.50 | −$29.50 | −$19.00 | −$23.50 |
| Gross margin | 100.0% | 100.0% | 100.0% | 98.0% | 45.5% | 75.4% | 87.2% | 83.0% | 84.3% | 78.4% |
| Operating margin | −139.4% | −275.1% | −654.6% | 15.2% | −3,092.8% | −239.8% | −304.6% | −808.8% | −462.7% | −466.3% |
| Net margin | −18.8% | −123.9% | −789.4% | 160.1% | −6,700.9% | −282.9% | −354.8% | −823.7% | −458.5% | −464.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $869,000 | $724,000 | $893,000 | $784,000 | $952,000 | $393,000 | $667,000 | $547,000 | $234,000 | $313,000 | $502,000 | $0 |
| Cost of revenue | $329,000 | $325,000 | $906,000 | $96,000 | $96,000 | $133,000 | $0 | $0 | $180,000 | $637,000 | $637,000 | $130,000 |
| Gross profit | $540,000 | $724,000 | $893,000 | $784,000 | $952,000 | $393,000 | $667,000 | $547,000 | $234,000 | $313,000 | −$135,000 | −$53,000 |
| Sales, general & admin | $1.6M | $1.4M | $2.3M | $1.5M | $1.6M | $1.5M | $879,000 | $1.6M | $1.2M | $3.1M | $3.1M | $1.6M |
| Total operating expenses | $1.3M | $1.4M | $2.4M | $1.6M | $1.6M | $1.6M | $986,000 | $1.7M | $3.0M | $1.5M | $1.5M | $1.7M |
| Operating income | −$803,000 | −$723,000 | −$1.5M | −$830,000 | −$695,000 | −$1.2M | −$319,000 | −$1.1M | −$2.8M | −$1.1M | −$1.6M | −$1.8M |
| Interest income | — | $41,000 | — | — | — | $29,000 | — | — | — | — | — | — |
| Interest expense | — | — | $1,000 | $3,000 | $2,000 | $2,000 | — | $3,000 | $5,000 | $85,000 | $85,000 | $20,000 |
| Income before taxes | $164,000 | $103,000 | −$580,000 | $50,000 | $545,000 | −$668,000 | $83,000 | −$567,000 | −$1.1M | −$809,000 | −$1.6M | −$1.4M |
| Income taxes | — | $8,000 | $32,000 | −$102,000 | −$6,000 | −$32,000 | −$31,000 | $42,000 | $40,000 | −$43,000 | −$43,000 | $2.3M |
| Net income | $155,000 | $95,000 | −$619,000 | $152,000 | $551,000 | −$653,000 | $252,000 | −$609,000 | −$1.1M | −$734,000 | −$883,000 | −$3.4M |
| EBITDA | −$474,000 | −$398,000 | −$3.2M | $149,000 | $643,000 | −$1.1M | −$974,000 | −$468,000 | −$865,000 | −$676,000 | −$974,000 | −$1.3M |
| EPS (diluted) | $0.01 | $0.00 | $0.00 | $0.00 | $0.05 | $0.02 | $0.02 | −$0.05 | −$0.09 | −$0.08 | −$0.08 | −$0.32 |
| Gross margin | 62.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −26.9% | — |
| Operating margin | −92.4% | −99.9% | −167.5% | −105.9% | −73.0% | −303.6% | −47.8% | −207.3% | −1,191.9% | −364.9% | −320.9% | — |
| Net margin | 17.8% | 13.1% | −69.3% | 19.4% | 57.9% | −166.2% | 37.8% | −111.3% | −465.8% | −234.5% | −175.9% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TXMD's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TXMD financial results
In fiscal year 2025 (ended December 31, 2025), TherapeuticsMD reported revenue of $3.0 million, up 71.6% from the year before. It had a net loss of $0.6 million, a net profit margin of −18.8%. Diluted earnings per share came to $0.07. Over five years revenue grew at an average rate of −45.8% a year.
See the TXMD stock overview for the latest quote and news, or the TXMD chart for price history and technical indicators.
TXMD income statement FAQ
What is TherapeuticsMD's annual revenue?
TherapeuticsMD reported total revenue of $3.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 71.6% from $1.8 million the previous year.
Is TherapeuticsMD profitable?
No. TherapeuticsMD reported a net loss of $0.6 million in fiscal 2025, a net profit margin of −18.8%; its operating margin was −139.4%.
What is TherapeuticsMD's gross margin?
TherapeuticsMD's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, TherapeuticsMD kept $100 after the direct cost of its products and services.
How fast is TherapeuticsMD growing?
Revenue grew −45.8% a year on average over the last five fiscal years, from $64.9 million to $3.0 million.
What are TherapeuticsMD's earnings per share?
TherapeuticsMD earned $0.07 per diluted share in fiscal 2025, compared with $-0.20 a year earlier.
When will TherapeuticsMD report its next earnings?
TherapeuticsMD is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does TherapeuticsMD's fiscal year end?
TherapeuticsMD's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.